Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 76

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 10
Chunk 76
---
 (2) tranches of $500,000 each by April 18, 2024 and May 15, 2024 (the “ Convertible Loan”). The Convertible Loan shall
bear interest of 12% per annum from the date it is remitted to April 30, 2025 (the “ Maturity Date”) or the date when the
Affluence sends the Company a written notice to convert any unpaid principal amount of the Convertible Loan with accrued interests (the
“ Outstanding Sum”) into ordinary shares of the Company (the “ Conversion Notice”), whichever is earlier. Anytime
on or before May 31, 2024, Affluence may send the Company a Conversion Notice to convert the then Outstanding Sum into ordinary shares
of the Company at $1.00 per share. Anytime after May 31, 2024, Affluence may send the Company a Conversion Notice to convert the then
Outstanding Sum into ordinary shares of the Company at $1.42 per share. The Company has no right of early repayment of any part of the
Convertible Loan without Affluence’s written consent. Any Outstanding Sum on the Maturity Date will be automatically converted
into ordinary shares of the Company at $1.42 per share.

  50  

On
January 16, 2024, we entered into a Convertible Loan Agreement with Gilandi Limited, a British Virgin Islands company (“ Gilandi”)
pursuant to which Gilandi has agreed to lend to the Company a convertible loan in the principal amount of $500,000 to be paid in two
(2) tranches of $250,000 each by January 31, 2024 and March 31, 2024 (the “ Gilandi Convertible Loan”). The Gilandi Convertible
Loan shall bear interests of 8% per annum until Mach 31, 2024. Outstanding balance of the Gilandi Convertible Loan on March 31, 2024
will automatically convert to the Company’s ordinary shares at $1.00 per share. On January 17, 2024, the Company sold and issued
to Gilandi convertible note in the principal amount of $250,000 pursuant to the Gilandi Convertible Loan Agreement. On March 28, 2024,
the Company received the second tranche of $250,000 from Gilandi. Pursuant to the Gilandi Loan Agreement, an aggregate amount of $500,000
of the loan automatically